Midazolam 2 mg for CYP3A4 phenotyping

DRUG2 trials

Sponsors

Advenchen Laboratories, LLC, Natalia Valadares de Moraes

Conditions

Alveolar Soft Part SarcomaBariatric SurgeryLeiomyosarcomaObesityRoux-en Y Gastric BypassSoft-Tissue SarcomaSynovial Sarcoma

Phase 3

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

RecruitingNCT03016819

Advenchen Laboratories, LLCAlveolar Soft Part Sarcoma, Leiomyosarcoma, Soft-Tissue Sarcoma +1

Start: 2017-08-15End: 2028-12-01Target: 325Updated: 2026-02-25

Phase 4

Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol

Natalia Valadares de MoraesBariatric Surgery, Obesity, Roux-en Y Gastric Bypass

Start: 2019-06-01End: 2023-08-31Target: 120Updated: 2022-02-08

Related Papers

A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).

Journal of Clinical Oncology2025-05-281 citations

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma.

Journal of Clinical Oncology2021-05-2025 citations